Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma

Lung Cancer

Volumn 90, Issue 1, 2015, Pages 111-117

  Yamagishi, Tomoko ^a   Fujimoto, Nobukazu ^a   Nishi, Hideyuki ^a   Miyamoto, Yosuke ^a   Hara, Naofumi ^a   Asano, Michiko ^a   Fuchimoto, Yasuko ^a   Wada, Sae ^a   Kitamura, Kenichi ^a   Ozaki, Shinji ^a   Kishimoto, Takumi ^a  

^a OKAYAMA ROSAI HOSPITAL   (Japan)

Author keywords

Asbestos; Lymphocyte to monocyte ratio; Malignant pleural mesothelioma; Prognostic score

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CELL RATIO; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLASGOW PROGNOSTIC SCORE; HISTOLOGY; HUMAN; INFLAMMATION; LYMPHOCYTE COUNT; LYMPHOCYTE TO MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; BLOOD; LUNG NEOPLASMS; LYMPHOCYTE; MESOTHELIOMA; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ASBESTOS; TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; ASBESTOS; BIOMARKERS, TUMOR; FEMALE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MESOTHELIOMA; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84940953915     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.07.014     Document Type: Article

References (39)

1. Gemba K., Fujimoto N., Kato K., Aoe K., Takeshima Y., Inai K., et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci. 2012, 103:483-490.
2. Cao C., Tian D., Park J., Allan J., Pataky K.A., Yan T.D. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 2014, 83:240-245.
3. Cao C., Tian D., Manganas C., Matthews P., Yan T.D. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann. Cardiothorac. Surg. 2012, 1:428-437.
4. Fennell D.A., Parmar A., Shamash J., Evans M.T., Sheaff M.T., Sylvester R., et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J. Clin. Oncol. 2005, 23:184-189.
5. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
6. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
7. Linton A., van Zandwijk N., Reid G., Clarke S., Cao C., Kao S. Inflammation in malignant mesothelioma-friend or foe?. Ann. Cardiothorac. Surg. 2012, 1:516-522.
8. Bugada D., Allegri M., Lavand'homme P., De Kock M., Fanelli G. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. Biomed. Res. Int. 2014, 2014:142425.
9. Pinato D.J., Mauri F.A., Ramakrishnan R., Wahab L., Lloyd T., Sharma R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J. Thorac. Oncol. 2012, 7:587-594.
10. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:806-867.
11. Lievense L.A., Bezemer K., Aerts J.G., Hegmans J.P. Tumor-associated macrophages in thoracic malignancies. Lung Cancer 2013, 80:256-262.
12. Porrata L.F., Inwards D.J., Ansell S.M., Micallef I.N., Johnston P.B., Hogan W.J., et al. Day 100 peripheral blood absolute lymphocyte/monocyte ratio and survival in classical Hodgkin's lymphoma postautologous peripheral blood hematopoietic stem cell transplantation. Bone Marrow Res. 2013, 658371. 10.1155/2013/658371.
13. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995, 108:1122-1128.
14. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 2005, 23:9067-9072.
15. Kao S.C., Pavlakis N., Harvie R., Vardy J.L., Boyer M.J., van Zandwijk N., et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin. Cancer Res. 2010, 16:5805-5813.
16. Feng Ji-Feng, Huang Ying, Chen Qi-Xun Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J. Surg. Oncol. 2014, 12:58.
17. McMillan D.C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat. Rev. 2013, 39:534-540.
18. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., O'Reilly D.S., Foulis A.K., et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br. J. Cancer 2011, 104:726-734.
19. Edwards J., Abrams K., Leverment J., Spyt T., Waller D., O'Byrne K. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000, 55:731-735.
20. Kinoshita A., Onoda H., Imai N., Iwaku A., Oishi M., Fushiya N., et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br. J. Cancer 2012, 107:988-993.
21. Bugada D., Allegri M., Lavand'homme P., De Kock M., Fanelli G. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. Biomed. Res. Int. 2014, 142425. 10.1155/2014/142425.
22. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., O'Reilly D.S., Foulis A.K., et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br. J. Cancer 2011, 104:726-734.
23. Fogar P., Sperti C., Basso D., Sanzari M.C., Greco E., Davoli C., et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006, 32:22-28.
24. Rabinowich H., Cohen R., Bruderman I., Steiner Z., Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 1987, 47:173-177.
25. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
26. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
27. Burt B.M., Rodig S.J., Tilleman T.R., Elbardissi A.W., Bueno R., Sugarbaker D.J. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011, 117:5234-5244.
28. Li Z.M., Huang J.J., Xia Y., Sun J., Huang Y., Wang Y., et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012, 7:e41658. 10.1371/journal.pone.0041658.
29. Stotz M., Pichler M., Absenger G., Szkandera J., Arminger F., Schaberl-Moser R., et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br. J. Cancer 2014, 110:435-440.
30. Ni X.J., Zhang X.L., Ou-Yang Q.W., Qian G.W., Wang L., Chen S., et al. An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. PLoS One 2014, 9:e111886. 10.1371/journal.pone.0111886.
31. Hu P., Shen H., Wang G., Zhang P., Liu Q., Du J. Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: based on a large cohort study. PLoS One 2014, 9:e108062. 10.1371/journal.pone.0108062.
32. Lin G.N., Peng J.W., Xiao J.J., Liu D.Y., Xia Z.J. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet. Med. Oncol. 2014, 31:70.
33. Fujiwara Y., Misawa T., Shiba H., Shirai Y., Iwase R., Haruki K., et al. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenocarcinoma. Anticancer Res. 2014, 34:5133-5138.
34. Temraz S., Mukherji D., Farhat Z.A., Nasr R., Charafeddine M., Shahait M., et al. Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol. 2014, 14:76.
35. Li J., Jiang R., Liu W.S., Liu Q., Xu M., Feng Q.S., et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One 2013, 8:e83069. 10.1371/journal.pone.0083069.
36. Mossman B.T., Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am. J. Respir. Crit. Care Med. 1998, 157:1666-1680.
37. Bograd A.J., Suzuki K., Vertes E., Colovos C., Morales E.A., Sadelain M., et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol. Immunother. 2011, 60:1509-1527.
38. Porrata L.F., Ristow K., Colgan J.P., Habermann T.M., Witzig T.E., Inwards D.J., et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012, 97:262-269.
39. Lameijer M.A., Tang J., Nahrendorf M., Beelen R.H., Mulder W.J. Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev. Mol. Diagn. 2013, 13:567-580.